BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:24:00 PM | Browse: 1383 | Download: 1833
 |
Received |
|
2014-01-11 14:42 |
|
Peer-Review Started |
|
2014-01-11 17:15 |
|
To Make the First Decision |
|
2014-01-23 17:19 |
|
Return for Revision |
|
2014-02-09 21:21 |
|
Revised |
|
2014-02-28 01:53 |
|
Second Decision |
|
2014-06-20 11:55 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2014-06-20 12:08 |
|
Articles in Press |
|
2014-06-20 13:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-08-11 08:39 |
|
Publish the Manuscript Online |
|
2014-08-20 20:37 |
| Category |
Rheumatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Charles J Malemud and David E Blumenthal |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Genentech/Roche Group and the Case Western Reserve University School of Medicine Visual Sciences Research Core |
P30 EY-011373 |
|
| Corresponding Author |
Charles J Malemud, PhD, Department of Medicine, Division of Rheumatic Diseases, The Arthritis Research Laboratory, Foley Medical Building, 2061 Cornell Road, Cleveland, OH 44106-5076,
United States. cjm4@cwru.edu
|
| Key Words |
Clinical trials; Protein kinase; Signal transduction; Small molecule inhibitor; Rheumatoid arthritis |
| Core Tip |
Signal transduction is a regulator of gene expression in cells. Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling is activated by pro-inflammatory cytokines which contributes to immune-mediated inflammation in rheumatoid arthritis. Medicinal chemistry was employed to develop JAK small molecule inhibitors for determining their clinical efficacy in active rheumatoid arthritis patients. Tofacitinib, a JAK small molecule inhibitor, is now generally used to treat moderate to severe rheumatoid arthritis patients who have not adequately responded to disease-modifying anti-rheumatic drugs or various biologic agents. The clinical efficacy of JAK small molecule inhibitors provides the impetus for future drug discovery targeted at other signal transduction pathways in rheumatoid arthritis. |
| Publish Date |
2014-08-20 20:37 |
| Citation |
Malemud CJ, Blumenthal DE. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives. World J Orthop 2014; 5(4): 496-503 |
| URL |
http://www.wjgnet.com/2218-5836/full/v5/i4/496.htm |
| DOI |
http://dx.doi.org/10.5312/wjo.v5.i4.496 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
